Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New pessary system aims to ease pelvic organ prolapse management at home

NCT ID NCT06634459

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jul 24, 2026 · Updated 3 times

Summary

This study tests a new pessary system designed for easier home use in women with pelvic organ prolapse. About 200 women who have never used a pessary will be randomly assigned to either the new system or standard care. The main goal is to see if the new system leads to higher satisfaction over six months.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Reia System (pessary and applicator) or standard pessary (Gellhorn or ring)
What this could lead to
If successful, this could offer women with pelvic organ prolapse a more convenient and satisfying way to manage their condition at home.
What could go wrong
This is a relatively small, early-stage trial focused on satisfaction and ease of use, not a cure. The new device may not prove better than standard options and could have unforeseen complications.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 218 people

The number the study aims to enrol. It can still change while the study runs.

Started

Nov 2024

Expected to finish

Jan 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * English-speaking natal females ≥ 18 years of age * Willing to self-maintain (insert/remove) pessary * Pessary naïve with Stage II-IV POP desiring conservative management with a pessary * Primary indication for use of pessary is treatment of pelvic organ prolapse Exclusion Criteria: * Primary indication for pessary use is for management of stress urinary incontinence * Prior mesh-augmented prolapse repair (i.e. transvaginal mesh, sacrocolpopexy) * Short vaginal length (TVL \< 8cm) or subjective vaginal narrowing * Vaginal fistula (e.g. rectovaginal, vesicovaginal or any type of fistula involving the vagina) * Vaginal, rectal or bladder malignancy * Genitourinary infection requiring treatment (See below 1) * Ongoing treatment for vaginal infections (e.g., chronic bacterial vaginosis) (See below 2) * Inflammatory bowel disease (Crohn's or ulcerative colitis) * Pelvic or anorectal chronic pain * Pelvic floor surgery within the past 6 months or planning to undergo pelvic floor surgery * Congenital malformation of the bladder, rectum or vagina * Pregnant or planning pregnancy in the next 6 months * Prior failure of pessary for POP * History of hydroureter, hydronephrosis, or impaired renal function secondary to prolapse 1. Patients with acute vaginal infections will be eligible for enrollment 2 weeks after completing treatment with resolution of symptoms 2. OK to be on prophylactic/suppressive therapy for HSV

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Pelvic organ prolapse are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Atrium Health Wake Forest Baptist

    Winston-Salem, North Carolina, 27103, United States

  • Dartmouth-Hitchcock

    Lebanon, New Hampshire, 03756, United States

  • MedStar Health

    Washington D.C., District of Columbia, 20010, United States

  • Stanford University

    Palo Alto, California, 94304, United States

  • The University of Chicago

    Northbrook, Illinois, 60062, United States

  • University of Alabama at Birmingham

    Birmingham, Alabama, 35249, United States

  • University of New Mexico Health Sciences Center

    Albuquerque, New Mexico, 87131, United States

  • University of Wisconsin

    Madison, Wisconsin, 53711, United States

  • Women & Infants Hospital in Rhode Island

    Providence, Rhode Island, 02903, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.